2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 | 2009 | 2005 | 2003 | 2002 | 1999 | All

O'Farrell A, Evans R, Silvola JMU, Miller IS, Conroy E, Hector S, Cary M, Murray DW, Jarzabek MA, Maratha A, Alamanou M, Mallya-Udupi G, Shiels L, Pallaud C, Saraste A, Lijenback H, Jauhiained M, Oikonen V, Ducret A, Cutler P, McAuliffe FM, Rousseau JA, Lecomte R, Gascon S, Arany Z, Ky Bonnie, Force T, Knuuti J, Gallagher WM, Roivainen A, Byrne AT .
A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate
PLOS ONE 10.1371/journal.pone.0169964     PMID: PMC5271313      (Jan 2017)

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C,. Chang DK, Clarke RB2, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek M, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mari Mælandsmo G, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L .
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nature Reviews Cancer 10.1038/nrc.2016.140     PMID: 28104906      (Jan 2017)

Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP,Schulte N .
Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative
Digestion. 2016 Oct 19;94(3):129-137. Epub ahead of print     PMID: 27756074      (Oct 2016)

Rudolph M, Anzeneder T, Schulz A, Beckmann G, Byrne AT, Jeffers M, Pena C, Politz O, Köchert K, Vonk R, Reischl J .
AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
BMC Cancer. 2016 Aug 11;16:622. doi: 10.1186/s12885-016-2626-1.     PMID: 27515171      (Aug 2016)

Besenhard MO, Jarzabek M, O'Farrell AC, Callanan JJ, Prehn JH, Byrne AT, Huber HJ. .
Modelling tumour cell proliferation from vascular structure using tissue decomposition into avascular elements.
J Theor Biol. 2016 Aug 7;402:129-43. doi: 10.1016/j.jtbi.2016.04.028.     PMID: 27155046      (Aug 2016)

Markus Joerger, Stephen P. Finn, Sinead Cuffe, Annette T. Byrne & Steven G. Gray .
The IL-17-Th1/Th17 pathway: An attractive target for lung cancer therapy?
Expert Opin Ther Targets. EPUB ahead of print     PMID: 27353429      (Jun 2016)

Boland K, Flanagan L, McCawley N, Pabari R, Kay EW, McNamara DA, Murray F, Byrne AT, Ramtoola Z, Concannon CG, Prehn JH. .
Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer.
Eur J Pharmacol. 2016 Jun 5;780:53-64. doi: 10.1016/j.ejphar.2016.03.031 Epub 2016 Mar 17.     PMID: 26997367      (Jun 2016)

O'Halloran PJ, Viel T, Murray DW, Wachsmuth L, Schwegmann K, Wagner S, Kopka K, Jarzabek MA, Dicker P, Hermann S, Faber C, Klasen T, Schäfers M, O'Brien D, Prehn JH, Jacobs AH, Byrne AT. .
Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
Eur J Nucl Med Mol Imaging Epub ahead of print     PMID: 26975402      (Mar 2016)

Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, Day BW, Boyd AW, Kögel D, Rehm M, O'Brien DF, Byrne AT, Prehn JH. .
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Br J Cancer. 2016 Jan 19;114(2):188-98 doi: 10.1038/bjc.2015.420     PMID: 26657652      (Dec 2015)

Szwej E, Devocelle M, Kenny S, Guzik M, O'Connor S, Nikodinovic-Runic J, Radivojevic J, Maslak V, Byrne AT, Gallagher WM, Zulian QR, Zinn M, O'Connor KE. .
The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.
J Biotechnol. 2015 Mar 24;204:7-12. doi:10.1016/j.jbiotec.2015.02.036     PMID: 25820126      (Mar 2015)

Byrne AT, Arnett R, Farrell T, Sreenan S .
Comparison of performance in a four year graduate entry medical programme and a traditional five/six year programme.
BMC Med Educ. 2014 Dec 10;14(1):248     PMID: 25491032      (Dec 2014)

Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT. .
Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models
Br J Cancer, 6 Nov 2014, doi:10.1038/bjc.2014.529     PMID: 25375271      (Nov 2014)

Van Cutsem E, Prager G, Sargent D, Byrne AT, Huber HJ, Middleton G, Khan K, De Mattos-Arruda L, Seufferlein T. .
Biomarker-driven Studies in Metastatic Colorectal Cancer (mCRC): Challenges and Opportunities
e Journal of OncoPathology, Volume 2, Number 4, November 2014, pp. 37-45(9)     PMID: N/A      (Nov 2014)

Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A .
Patient-derived xenograft models: an emerging platform for translational cancer research
Cancer Discov. 2014 Sep;4(9):998-1013. doi:10.1158/2159-8290.CD-14-0001     PMID: 25185190      (Sep 2014)

Sweeney KJ, Jarzabek MA, Dicker P, O'Brien DF, Callanan JJ, Byrne AT, Prehn JH .
Validation of an imageable surgical resection animal model of Glioblastoma (GBM).
J Neurosci Methods,18 June 2014;233C:99-104, doi:10.1016/j.jneumeth.2014.05.006     PMID: 24952322      (Jun 2014)

Temple D, Denis R, Walsh MC, Dicker P, Byrne AT .
Comparison of anthropometric-based equations for estimation of body fat percentage in a normal-weight and overweight female cohort: validation via air-displacement plethysmography
Public Health Nutr.2014 Apr 16:1-7.     PMID: 24735997      (Apr 2014)

Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS,Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT, O'Driscoll L. .
Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors.
Cancer Res. 2014 Jul 15;74(14):3821-33. doi: 10.1158/0008-5472.CAN-13-2053.     PMID: 24876102      (Mar 2014)

Murray DW, Didier S, Chan A, Paulino V, Van Aelst L, Ruggieri R, Tran NL, Byrne AT, Symons M .
Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation
British Journal of Cancer, 11 February 2014; doi:10.1038/bjc.2014.39     PMID: 24518591      (Feb 2014)

Jarzabek MA, Sweeney KJ, Evans RL, Jacobs AH, Stupp R, O'Brien D, Berger MS, Prehn JH, Byrne AT .
Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary
Drug Discov Today 2013 Jun 20,Epub ahead of print     PMID: 23792334      (Jun 2013)

Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT .
In Vivo Bioluminescence Imaging Validation of a Human Biopsy-derived Orthotopic Mouse Model of Glioblastoma Multiforme
Mol Imaging 2013 12:1-12     PMID: 2013      (Mar 2013)

O'Connor S, Szwej E, Nikodinovic-Runic J, O'Connor A, Byrne AT, Devocelle M, O'Donovan N, Gallagher WM, Babu R, Kenny ST, Zinn M, Zulian QR, O'Connor KE .
The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.
Biomaterials. 2013 Apr 34(11):2710-8     PMID: PubMed PMID: 23343631      (Jan 2013)

Vader P, van der Meel R, Symons M H, Fens M H A M, Pieters E, Wilschut K J, Storm G, Jarzabek M, Gallagher W, Schiffelers R M, Byrne A T .
Examining the Role of Rac1 in Tumour Angiogenesis and Growth: A clinically Relevant RNAi-mediated Approach
Angiogenesis     PMID:      (Aug 2011)

Hams E, Saunders SP, Cummins EP, O'Connor A, Tambuwala MT, Gallagher WM, Byrne AT, Campos-Torres A, Moynagh PM, Jobin C, Taylor CT, Fallon PG .
The Hydroxylase Inhibitor DMOG Attenuates Endotoxic Shock via Alternative Activation of Macrophages and IL-10 Production by B-1 cells
Shock. In Press     PMID:      (May 2011)

O'Connor AE, McGee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM .
Mechanism of cell death mediated by a BF(2) -chelated tetraryl-azadipyrromethene photodynamic therapeutic: Dissection of the apoptotic pathway in vitro and in vivo
International Journal of Cancer - Epub ahead of print     PMID: 21413012      (Mar 2011)

van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT .
The VEGF/Rho GTPase signalling pathway: a promising target for antiangiogenic and anti-invasion therapy
Drug Discov Today, In Press     PMID: 21262381      (Feb 2011)

Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, O'Connor A, Gallagher WM, Lenihan CR, Garvey JF, Howell K, Fallon PG, Cummins EP, Taylor CT .
An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia
J Immunol. 2011 Jan 15;186(2):1091-6     PMID: 21149600      (Dec 2010)

O'Donovan N, Byrne A, O'Connor AE, McGee S, Gallagher WM, Crown J .
Synergistic interaction between Trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells
Invest New Drugs     PMID: 20229355      (Mar 2010)

O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT .
Bioluminescent imaging: a critical tool in pre-clinical oncology research
J Pathol     PMID: 19967724      (Feb 2010)

Fens MH, Storm G, Pelgrim RC, Ultree A, Byrne AT, Gaillard CA, van Solinge WW, Schiffelers RM .
Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability
Exp Hematol     PMID: 20146933      (Feb 2010)

van der Meel R, Gallagher WM, Oliveira S, O'Connor AE, Schiffelers RM, Byrne AT .
Recent advances in molecular imaging biomarkers in cancer: application of bench to bed technologies
Drug Discov Today     PMID: 20035896      (Dec 2009)

Byrne AT, O'Connor AE, Hall M, Murtagh J, O'Neill K, Curran KM, Mangrain K, Rousseau JA, Lecomte R, McGee S, Callanan JJ, O'Shea DF, Gallagher WM .
Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment
Br J Cancer     PMID: 19826417      (Nov 2009)

O'Connor AE, Gallagher WM, Byrne AT .
Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy.
Photochem Photobiol     PMID: 19682322      (Sep 2009)

McDonnell SO, Hall MJ, Allen LT, Byrne A, Gallagher WM, O'Shea DF .
Supramolecular photonic therapeutic agents
J Am Chem Soc. 2005 Nov 30;127(47):16360-1     PMID: 16305199      (Nov 2005)

Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, .
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model
Clin Cancer Res. 2003 Nov 15;9(15):5721-8.     PMID: 14654557      (Nov 2003)

Byrne AT, Southgate J, Brison DR, Leese HJ .
Effects of insulin-like growth factors I and II on tumour-necrosis-factor-alpha-induced apoptosis in early murine embryos
Reprod Fertil Dev. 2002;14(1-2):79-83     PMID: 12051527      (Dec 2002)

Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB .
Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2
J Clin Endocrinology & Metabolism, 2002 Sep 87(9):4213-24     PMID: 12213874      (Sep 2002)

Byrne AT, Southgate J, Brison DR, Leese HJ. .
Regulation of apoptosis in the bovine blastocyst by insulin and the insulin-like growth factor (IGF) superfamily
Mol Reprod Dev. 2002 Aug;62(4):489-95.     PMID: 12112582      (Aug 2002)

Byrne AT, Southgate J, Brison DR, Leese HJ .
Analysis of apoptosis in the preimplantation bovine embryo using TUNEL
J Reprod Fertil. 1999 Sep;117(1):97-105     PMID: 10645250      (Sep 1999)